# Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

> **NCT00193206** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 123 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Epirubicin
- **DRUG:** Albumin-bound Paclitaxel

## Key facts

- **NCT ID:** NCT00193206
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-10
- **Final completion:** 2009-05
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193206, "Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00193206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*